Literature DB >> 2079659

Application of the NONMEM method to evaluation of the bioavailability of drug products.

N Kaniwa1, N Aoyagi, H Ogata, M Ishii.   

Abstract

The NONMEM method, one of the methods used for analysis of population pharmacokinetics, was applied to the evaluation of the relative bioavailability of drug products. The data of 2 x 2 crossover studies of several drugs and a 3 x 3 crossover study of phenytoin using healthy volunteers were analyzed by the NONMEM method, as well as by the confidence interval procedure, which is a standard approach to the bioequivalence test data using model-independent parameters. Very close confidence intervals for the relative difference in bioavailability were estimated by the NONMEM method and the standard approach, both in cases where products were bioequivalent and where they were not. The NONMEM method could also correctly estimate the relative bioavailability of the products using simulated clinical data obtained by randomly reducing the sampling points of the phenytoin data mentioned above, which cannot be analyzed by the standard approach. Thus, the usefulness of the NONMEM method was confirmed for evaluation of bioavailability using clinical or experimental data.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2079659     DOI: 10.1002/jps.2600791215

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  12 in total

1.  Characterization of the highly variable bioavailability of tiludronate in normal volunteers using population pharmacokinetic methodologies.

Authors:  G A Maier; G F Lockwood; J A Oppermann; G Wei; P Bauer; J Fedler-Kelly; T Grasela
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jul-Sep       Impact factor: 2.441

2.  Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

Authors:  Xiaoyu Yan; Philip J Lowe; Martin Fink; Alexander Berghout; Sigrid Balser; Wojciech Krzyzanski
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

3.  Statistical issues in a modeling approach to assessing bioequivalence or PK similarity with presence of sparsely sampled subjects.

Authors:  Chuanpu Hu; Katy H P Moore; Yong H Kim; Mark E Sale
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-08       Impact factor: 2.745

4.  Pharmacokinetic similarity of biologics: analysis using nonlinear mixed-effects modeling.

Authors:  A Dubois; S Gsteiger; S Balser; E Pigeolet; J L Steimer; G Pillai; F Mentré
Journal:  Clin Pharmacol Ther       Date:  2011-12-28       Impact factor: 6.875

5.  Bioequivalence tests based on individual estimates using non-compartmental or model-based analyses: evaluation of estimates of sample means and type I error for different designs.

Authors:  Anne Dubois; Sandro Gsteiger; Etienne Pigeolet; France Mentré
Journal:  Pharm Res       Date:  2009-10-30       Impact factor: 4.200

6.  Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam.

Authors:  M Hossain; E Wright; R Baweja; T Ludden; R Miller
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

7.  Bioequivalence: individual and population compartmental modeling compared to the noncompartmental approach.

Authors:  H S Pentikis; J D Henderson; N L Tran; T M Ludden
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

Review 8.  Generic drugs. Therapeutic equivalence.

Authors:  P A Meredith
Journal:  Drug Saf       Date:  1996-10       Impact factor: 5.606

9.  The importance of modeling interoccasion variability in population pharmacokinetic analyses.

Authors:  M O Karlsson; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1993-12

10.  Bioavailability of controlled release carbamazepine estimated by mixed effect modelling.

Authors:  R Miller; T M Ludden
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.